PHLT 8046 Week 9 Human Subjects Protection Plan Example

Course	PHLT 8046 Grant Writing and Review for Public Health Research
Week	Week 9
Paper type	Human subjects plan
Length	About 1,100 words, 7 pages
Format	APA 7 student paper
School	Walden University
Program	PhD in Public Health
Updated	October 2026

Free sample paper for PHLT 8046 Week 9

Human Subjects Protection Plan for Enrolling Children in a Sham-Controlled HEPA Air Cleaner Trial: Risk Level, Permission and Assent, Confidentiality, In-Home Burden and Why Each Safeguard Is Sufficient

Student Name

Walden University

PHLT 8046: Grant Writing and Review for Public Health Research

Instructor Name

Month Day, Year

What this page is doingThe title promises an argument for sufficiency, because a protection plan that only lists safeguards reads as a set of promises.

Overview

The trial will enroll 300 young people between 6 and 17 whose asthma is persistent, randomizing them to a working HEPA air cleaner or a sham unit in their bedrooms for two wildfire seasons. It falls under the federal human subjects rules, including the additional protections for children (45 C.F.R. § 46.404). This plan explains, for each risk the study creates, the safeguard that answers it and why that safeguard is enough. It draws on the widely used account of what makes clinical research ethical, which asks whether a study has value and a design capable of settling what it asks, whether participants are chosen fairly and face acceptable risks for the expected benefits, whether outside reviewers have approved it, whether people agree knowingly, and whether they are treated with respect once enrolled (Emanuel et al., 2000).

What this page is doingFraming the plan around the risk each safeguard answers makes sufficiency something a reviewer can judge.

Risk Level and Regulatory Category

The study's procedures carry minimal risk. Portable HEPA cleaners filter air mechanically; the selected model has no ionizer or ozone-generating component, so it adds no pollutant. Sham units run the fan without the filter, which neither adds nor removes risk compared with ordinary room air. Particle sensors are passive. Data come largely from existing health records. The remaining risks are noise, minor inconvenience from home visits, the small chance that a sensor or cleaner malfunctions, and the possibility that confidential information is disclosed. Because the research as a whole involves no more than minimal risk, it falls in the category of research with children that may be approved with adequate provisions for permission and assent (45 C.F.R. § 46.404).

The Sham Arm and Equipoise

Assigning half the children to a sham unit is ethically acceptable only if there is genuine uncertainty about whether the working cleaner prevents urgent asthma visits. Freedman (1987) located the justification for randomized comparison in honest professional disagreement about which arm is better. That condition holds here: cleaners lower indoor particles, but whether they prevent urgent visits during episodic wildfire smoke is untested, and the significance section documents the gap. Sham-arm children also receive everything children in the county receive now, including usual asthma care and public smoke advisories, plus smoke-day text alerts sent to both arms. No effective treatment is withheld.

After the Trial

Because sham-arm families give their time without the possibility of benefit from the device, the team has arranged with a county foundation to provide each sham-arm family with an active cleaner when follow-up ends. This step reflects respect for enrolled participants and is described to families at consent.

Permission and Assent

For research involving no more than minimal risk, the permission of one parent or guardian is sufficient under the federal rules, and the review board may require more. Permission will be obtained in person by bilingual community health workers, in English or Spanish, using a plain-language form pitched for readers who left school early, which staff will read aloud whenever asked. The form explains randomization in plain words, including that families will not know whether their unit has a filter until the study ends.

Assent will be sought from every child aged 7 and older, using an age-appropriate script for children 7 to 11 and a written assent form for adolescents 12 to 17 (45 C.F.R. § 46.408). Six-year-olds will be told about the study in simple terms and their agreement noted. A child's refusal to assent will be respected even if the parent consents. Adolescents will be told that they may ask questions privately.

Why These Measures Are Sufficient

Permission and assent are sufficient here because the procedures are minimal risk, the study offers no inducement beyond reasonable compensation and electricity reimbursement, and consent occurs in families' homes and languages with time to consider. Families may withdraw at any time without affecting their child's health care or Medicaid coverage, and the form says so explicitly.

Confidentiality

The study holds three kinds of sensitive information: health records, home addresses linked to sensor data, and survey responses about household circumstances. Each is protected in a specific way. Records from Medicaid plans and health centers will be transferred through secure systems under data use agreements and stored on the institution's encrypted research server, with access limited to named staff. Sensor data will be stored with study identification numbers only; the key linking identifiers to addresses will be kept separately. Survey data will be entered without names. The study will be covered by a Certificate of Confidentiality, which protects identifiable information from compelled disclosure in legal proceedings and applies automatically to research funded by the National Institutes of Health (National Institutes of Health [NIH], 2017). Findings will be reported only in aggregate.

Why These Measures Are Sufficient

The main confidentiality risk is that a family's participation, health information or address becomes known to others. Separating identifiers from data, limiting access, encrypting storage and adding legal protection against compelled disclosure address each route by which information could leak. The residual risk is low and comparable to that of routine health care records.

What this page is doingExplaining why each confidentiality safeguard closes a specific route of disclosure is what turns the section from promises into an argument.

Burden in the Home

Running a device in a child's bedroom for two seasons is an ongoing presence. Families will receive four data collection visits a year and quarterly filter visits, each scheduled at the family's convenience and lasting under 30 minutes. The cleaner's noise at its recommended setting is similar to a quiet fan; families may lower the setting at night, and field staff will record any concerns. Electricity costs are reimbursed. If a family finds the unit intolerable, they may switch it off or withdraw, and the team will collect the unit within a week.

Safety Monitoring

An independent data safety monitoring board of three members, including a pediatric pulmonologist and a biostatistician, will review enrollment, adverse events and data quality twice a year. Because urgent asthma visits are the trial's outcome, they will not be reported as adverse events, but any event plausibly related to the devices, such as an electrical fault or injury, goes to the review board in no more than five business days. The board may recommend stopping the trial for unexpected harm.

Inclusion

The study includes children of all sexes, races and ethnicities who meet eligibility criteria, and recruitment through Medicaid plans and health centers ensures that low-income children, who bear a disproportionate asthma burden, are well represented. Children under 6 are excluded because asthma diagnosis is less certain at younger ages and the outcome definitions differ. Adults are excluded because the research question concerns children.

References

Emanuel, E. J., Wendler, D., & Grady, C. (2000). What makes clinical research ethical? JAMA, 283(20), 2701-2711. https://doi.org/10.1001/jama.283.20.2701

Freedman, B. (1987). Equipoise and the ethics of clinical research. The New England Journal of Medicine, 317(3), 141-145. https://doi.org/10.1056/NEJM198707163170304

National Institutes of Health. (2017). Announcing revised NIH policy for issuing Certificates of Confidentiality (Notice No. NOT-OD-17-109).

Protection of Human Subjects, Assent and Permission, 45 C.F.R. § 46.408 (2024).

Protection of Human Subjects, 45 C.F.R. § 46.404 (2024).

PHLT 8046 Week 9 instructions, in plain terms

The ninth assignment usually asks for the protection of human subjects section of a research application. Faculty expect the plan to identify the study's risk level and regulatory category, describe consent, permission and assent procedures, explain confidentiality protections and address burden and safety monitoring, with a justification for including or excluding particular groups. For research with children, the additional federal protections apply and should be cited. Strong plans explain why each safeguard is sufficient for the specific risk it answers, rather than listing safeguards. Where a control group receives a sham or no intervention, equipoise and post-trial access should be addressed. Plans are written in the register an institutional review board expects. About four to five pages is typical, organized under the headings the funder's instructions require.

How this PHLT 8046 Week 9 example is built

An overview introduces the trial and frames the plan around the conditions that make research ethical. A risk section explains why the procedures carry minimal risk and places the study in the regulatory category for such research with children. Subsections defend the sham arm on equipoise and describe post-trial cleaners for sham families. A permission and assent section describes bilingual consent at home, age-appropriate assent and the right to refuse, then explains why the measures suffice. A confidentiality section covers each kind of sensitive data and the Certificate of Confidentiality, again with a sufficiency argument. Sections address in-home burden, safety monitoring by an independent board and inclusion across sex, race, ethnicity and age, with reasons for excluding younger children and adults.

PHLT 8046 Week 9 rubric: what earns full marks

Graders reward a plan that argues sufficiency for each safeguard. Plans that list protections without connecting them to specific risks earn less. Credit goes to an accurate risk determination and regulatory category, a defensible account of equipoise for the sham arm, and attention to post-trial access. Permission and assent procedures should be appropriate to the children's ages and the families' languages, and the right to withdraw should be explicit. Confidentiality protections should address each type of data. Burden on families and safety monitoring should be described concretely. Accurate citation of federal regulations and the ethics literature supports the reasoning. The plan should be consistent with the approach and budget, for example in visit frequency and electricity reimbursement.

PHLT 8046 Week 9 help: mistakes that cost marks

Human subjects plans often read as checklists of safeguards. For each risk your study creates, name the safeguard and explain why it is enough. Determine your risk level carefully and cite the right regulatory category. If you use a sham or control, explain why genuine uncertainty justifies it and what controls receive afterward. Fit consent and assent to ages and languages. Show how each kind of data is protected. Plans for other studies with children can follow the same risk-by-risk structure.

Get a PHLT 8046 Week 9 example written to your instructions

A plan pairing each risk with an argued safeguard arrives in 24-48h when the protections prompt and rubric come with a description of your design and population; the first is free. No clinic recruited the example's families and no IRB reviewed its trial, so the protections in your plan answer the risks your own study creates.

More PHLT 8046 papers and PhD in Public Health samples

PHLT 8046 Week 9 questions, answered

Does a class human subjects plan go to a real IRB?

Usually not; it is written as though for IRB review but graded by faculty. If your course project involves collecting data, approval through your institution's IRB comes first and follows its own forms. The example is written in the register an IRB expects, so the reasoning transfers directly when a real submission arrives later in the program.

What do federal rules require for research with children?

HHS regulations add protections for children on top of the Common Rule, requiring, among other things, permission from parents or guardians and assent from children capable of giving it, with the level of risk shaping what an IRB can approve. The example argues its trial poses minimal risk and describes assent pitched to age. Your IRB's own guidance defines how assent is documented at different ages.

Is a sham control ethical in a study like this?

It can be, when participants are told they may receive either device, when standard guidance continues in both arms, and when the control group receives the active intervention afterward. The example defends all three conditions in its plan. Whether a sham suits your study depends on the risk of withholding the intervention, which your plan has to weigh openly.

Where can I find a free PHLT 8046 Week 9 sample paper?

The full Week 9 human subjects plan is on this page, defending minimal-risk enrollment of children in a sham-controlled HEPA trial with permission, assent, confidentiality and monitoring.

Why is one parent's permission enough in this trial?

Federal rules allow one parent's permission for research involving no more than minimal risk to children, and the cleaner and sensors add no meaningful risk, though a review board may require more.